Pepgen INC 10-Q quarterly reports

PepGen Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued research and development expenses, progress on its PGN-EDODM1 candidate, and a partial clinical hold in the U.S.

PepGen Inc. reported a net loss of $17.8 million for Q1 2026, with a significant decrease in R&D expenses and a cash runway extending into the second half of 2027.

PepGen Inc. reported a significant increase in cash and cash equivalents to $142.8 million following a $107.6 million public offering, extending its cash runway into the second half of 2027, despite discontinuing its Duchenne muscular dystrophy program.

PepGen Inc. announced the discontinuation of its Duchenne muscular dystrophy program, PGN-EDO51, due to insufficient dystrophin levels, shifting focus to its Myotonic Dystrophy Type 1 candidate, PGN-EDODM1, amidst substantial doubt about its ability to continue as a going concern.

PepGen Inc. announces its Q1 2025 financial results, highlighting increased R&D spending and providing updates on its PGN-EDO51 and PGN-EDODM1 clinical programs.

PepGen Inc. released its third quarter 2024 financial results, highlighting progress in clinical trials for its lead product candidates and providing updates on its financial position.

PepGen Inc. reports a net loss of $46.4 million for the first six months of 2024, while highlighting progress in clinical trials for its lead product candidates.

PepGen Inc. reports a net loss of $18.0 million for the first quarter of 2024, while highlighting progress in clinical trials and pipeline development.